Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy

Author(s): Weiqiang Zhou, Shanchun Guo, Mingli Liu, Matthew E. Burow, Guangdi Wang*.

Journal Name: Current Medicinal Chemistry

Volume 26 , Issue 17 , 2019

Become EABM
Become Reviewer

Abstract:

Chemokines, which have chemotactic abilities, are comprised of a family of small cytokines with 8-10 kilodaltons. Chemokines work in immune cells by trafficking and regulating cell proliferation, migration, activation, differentiation, and homing. CXCR-4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1, also known as CXCL12), which has been found to be expressed in more than 23 different types of cancers. Recently, the SDF-1/CXCR-4 signaling pathway has emerged as a potential therapeutic target for human tumor because of its critical role in tumor initiation and progression by activating multiple signaling pathways, such as ERK1/2, ras, p38 MAPK, PLC/ MAPK, and SAPK/ JNK, as well as regulating cancer stem cells. CXCL12/CXCR4 antagonists have been produced, which have shown encouraging results in anti-cancer activity. Here, we provide a brief overview of the CXCL12/CXCR4 axis as a molecular target for cancer treatment. We also review the potential utility of targeting CXCL12/CXCR4 axis in combination of immunotherapy and/or chemotherapy based on up-to-date literature and ongoing research progress.

Keywords: Cancer, cancer stem cell, immunotherapy, CXCR4, CXCL12, chemokine, kilodaltons.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 17
Year: 2019
Page: [3026 - 3041]
Pages: 16
DOI: 10.2174/0929867324666170830111531
Price: $95

Article Metrics

PDF: 40